

1 **JAK signaling was involved in the pathogenesis of Polymyalgia Rheumatica**

2 Fan Yang^{1,*}, Xinlei Ma^{2,*}, Bei Xu^{2,*}, Yiduo Sun², Mengdi Jiang², Chunyun Ren²,
3 Chuanying Sun², Junyu Liang², Heng Cao², Danyi Xu², Lihuan Yue², Liqin Xu², Jin Lin²,
4 Weiqian Chen²

5

6 ¹State Key Laboratory of Infectious Diseases Diagnosis and Treatment, the First
7 Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003
8 Zhejiang, China

9 ²Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of
10 Medicine, Hangzhou, 310003 Zhejiang, China

11

12 **Running title:** JAK signaling was highly activated in patients with PMR

13

14 * Fan Yang, Xinlei Ma, and Bei Xu equally contributed to this manuscript.

15

16 Correspondence to: Weiqian Chen, Email: cwq678@zju.edu.cn , Address: #79, Qing
17 Chun Road, Hangzhou, 310003, Zhejiang, China

18

19

20

21

22

23

24

25

26

27 **Abstract**

28 **Objectives.** Polymyalgia Rheumatica (PMR) is a common inflammatory disease in
29 elderly persons whose pathogenesis is unclear. We aimed to explore the
30 pathogenetic features of PMR and find a new therapeutic strategy.

31 **Methods.** We included 11 patients with PMR and 20 age-matched and sex-matched
32 healthy controls (HC) in this study. The disease features were described. The gene
33 expression profiles were analyzed in peripheral blood mononuclear cells (PBMCs) by
34 RNA sequencing and were confirmed by RT-PCR. We also tested gene expression
35 profiles in five patients with PMR after tofacitinib therapy.

36 **Results.** Patients with PMR experienced pain with high disease activity scores. The
37 gene expression of PBMCs in patients with PMR differed from that in HC by RNA
38 sequencing. GO and KEGG analysis demonstrated that inflammatory response and
39 cytokine-cytokine receptor interaction were the most remarkable pathways. There
40 were markedly expanded IL6R, IL1B, IL1R1, JAK2, TLR2, TLR4, TLR8, CCR1, CR1,
41 S100A8, S100A12, and IL17RA expressions. Those genes may trigger the JAK signaling.
42 Furthermore, tofacitinib, a pan JAK inhibitor, effectively treated five patients with
43 PMR, leading to clinical remission and a significant decrease in inflammatory genes.

44 **Conclusions.** Many inflammatory genes associated with JAK signaling were increased
45 in patients with PMR, suggesting an important role of JAK signaling in PMR disease
46 development. JAK inhibitors may effectively treat PMR.

47

48 **Keywords:** Polymyalgia Rheumatica, Inflammatory pathway, JAK signaling

49

50 **Key messages**

51 1. Patients with PMR had significant inflammatory genes expression. JAK signaling
52 may be highly activated.

53 2. Tofacitinib may treat PMR with clinical remission and a significant decrease in
54 inflammatory genes.

55

56

57 **Introduction**

58 Polymyalgia Rheumatica (PMR) is an inflammatory disease in elderly patients (>50
59 years old) characterized by pain and early morning stiffness in the shoulder, neck, and
60 pelvic girdle[1, 2]. Blood tests show higher serum levels of inflammatory markers such
61 as c-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in these
62 patients; however, negative results of rheumatoid factor (RF), and anti-citrullinated
63 protein/peptide antibody (ACPA), anti-nuclear antibodies (ANA), and human
64 leukocyte antigen B27 (HLA-B27). Sometimes, it is difficult to distinguish patients
65 with PMR from those with Rheumatoid arthritis (RA) who are negative for RF or
66 ACPA. However, patients with PMR usually have hallmark features with a dramatic
67 response to glucocorticoids.

68 PMR is a multi-gene susceptibility disease, and many alleles may be involved in the
69 pathogenesis of this disease[3]. Interleukin 6 (IL6) polymorphisms are associated
70 with PMR risk or severity[4]. Aging is a crucial element as PMR occurs in elderly
71 patients. Aging may increase the susceptibility to infectious agents, immune
72 responses, or the release of cytokines[5]. However, its pathogenesis has not been
73 fully elucidated. Further pathogenetic research and the discovery of new targets can
74 provide more ideas for the treatment of PMR.

75

76 **Methods**

77 **Subjects**

78 This cohort study included PMR patients who fulfilled the 1982 Chuang criteria[6]
79 between September 2020 and September 2021. They did not receive any
80 glucocorticoids or biological agents during the three-month period that preceded
81 their inclusion in the study. There were twenty age-matched and sex-matched
82 healthy controls (HC) without connective tissue disorders, neoplasms, or current
83 infections. All patients gave their written informed consent. The study was
84 performed according to the recommendations of the Declaration of Helsinki and was
85 approved by the Medical Ethical Committee of the First Affiliated Hospital, Zhejiang
86 University (IIT20200070C-R1).

87

88 **Clinical features**

89 Patient information on demographic data, clinical features, serological profiles, and
90 medications was obtained from medical records. Current PMR disease activity was
91 measured using the previous score sheet[7].

92

93 **RNA sequence analysis and Semiquantitative Real-Time PCR**

94 Peripheral blood mononuclear cells (PBMCs) were isolated from patients with PMR
95 and HC. Total RNA and RNA-seq libraries were prepared. Sequencing was performed
96 on an Illumina HiSeq1500. Some genes were tested by semiquantitative Real-Time
97 PCR. The primers for the target gene were described as below.

98 IL6R Forward: 5'-CCCCTCAGCAATGTTGTTTGT-3'

99 Reverse: 5'-CTCCGGGACTGCTAACTGG-3'

100 IL1B Forward: 5'-ATGATGGCTTATTACAGTGGCAA-3'

101 Reverse: 5'-GTCGGAGATTCGTAGCTGGA-3'

102 Interleukin 1 receptor type 1 (IL1R1)

103 Forward: 5'-ATGAAATTGATGTTCCCTGT-3'

104 Reverse: 5'-ACCACGCAATAGTAATGTCCTG-3'

105 Janus kinase (JAK) 2

106 Forward: 5'-TCTGGGGAGTATGTTGCAGAA-3'

107 Reverse: 5'-AGACATGGTTGGGTGGATAACC-3'

108 Toll Like Receptor 2 (TLR2)

109 Forward: 5'-ATCCTCCAATCAGGCTTCTCT-3'

110 Reverse: 5'-GGACAGGTCAAGGCTTTTTACA-3'

111 TLR4 Forward: 5'-AGACCTGTCCCTGAACCCTAT-3'

112 Reverse: 5'-CGATGGACTTCTAAACCAGCCA-3'

113 TLR8 Forward: 5'-ATGTTCCCTCAGTCGTCATGC-3'

114 Reverse: 5'-TTGCTGCACTCTGCAATAACT-3'

115 Interleukin 17 Receptor A (IL17RA)

116 Forward: 5'-GCTTCACCCTGTGGAACGAAT-3'

117 Reverse: 5'-TATGTGGTGCATGTGCTCAAA-3'

118 Complement receptor 1 (CR1)

119 Forward: 5'-AGAGGGACGAGCTTCGACC-3'

120 Reverse: 5'-TCAGGACGGCATTCTGACTTT-3'

121 C-C motif chemokine receptor 1 (CCR1)

122 Forward: 5'-GACTATGACACGACCACAGAGT-3'

123 Reverse: 5'-CCAACCAGGCCAATGACAAATA-3'

124 S100 calcium-binding protein A8 (S100A8)

125 Forward: 5'-ATGCCGTCTACAGGGATGAC-3'

126 Reverse: 5'-ACTGAGGACACTCGGTCTCTA-3'

127 S100A12 Forward: 5'-AGCATCTGGAGGGAATTGTCA-3'

128 Reverse: 5'-GCAATGGCTACCAGGGATATGAA-3'

129 GAPDH Forward: 5'-GGAGCGAGATCCCTCCAAAAT-3'

130 Reverse: 5'-GGCTGTTGTCATACTTCTCATGG-3',

131 GAPDH was considered as a normalization control. The data were

132 examined using the $2^{-\Delta\Delta CT}$ method and results were expressed as a fold increase.

133 Each sample was tested in triplicate, and tests were repeated three times.

134

135 **Statistical analysis**

136 Results are expressed as median and standard deviation (SD). Comparisons between

137 two groups were performed using the nonparametric Mann-Whitney test. *P*-values

138 < 0.05 were considered statistically significant. All statistical analyses were

139 performed using SPSS software, version 18.0.

140

141 **Results**

142 **The patients with PMR were in a state of high inflammation**

143 The baseline characteristics of the 11 PMR patients and 20 healthy controls are

144 presented in the supplementary material. There were no significant differences in

145 age and sex between the PMR group and HC. In the PMR group, patients who

146 experienced pain in the shoulder, neck, and pelvic girdle had a mean VS score of 4.9

147 \pm 2.2. They had higher serum levels of CRP (3.9 ± 3.1 mg/dl, normal range 0–0.08)

148 and ESR (67.1 ± 24.9 mm/L, normal range 0–20). Disease activity scores[7] ranged

149 from 9.33 to 27.15 with a mean value of 16.3 ± 7.3 (Table 1), which suggests medium

150 or high disease activity in these patients who were categorized as active PMR (PMR-
151 A). They were all negative for RF, ACPA, ANA, and HLA-B27. They represented no
152 remarkable wrist, metacarpophalangeal, proximal interphalangeal, knee, and digital
153 joint swelling.

154

155 **Patients with PMR had significant inflammatory gene expression profiles**

156 The principal component analysis (PCA) and heatmap showed that gene expressions
157 of PBMCs in patients with PMR-A differed from those of HC (Fig. 1A, B). GO analysis
158 demonstrated that the inflammatory response ($FDR\ 6.74 \times 10^{-15}$, included 58
159 significantly altered genes), plasma membrane (7.30×10^{-12} , included 254
160 significantly altered genes), integral component of the plasma membrane ($5.23 \times$
161 10^{-11} , included 115 significantly altered genes), extracellular space (2.76×10^{-8} ,
162 included 103 significantly altered genes), extracellular region (4.36×10^{-8} , included
163 116 significantly altered genes), response to lipopolysaccharide (2.42×10^{-6} , included
164 27 significantly altered genes), integral component of membrane (1.36×10^{-5} ,
165 included 270 significantly altered genes), immune response (1.21×10^{-4} , included 42
166 significantly altered genes), cell surface (2.04×10^{-4}), innate immune response (4.29
167 $\times 10^{-4}$), response to glucocorticoid (7.43×10^{-4}), IL-1 β secretion (1.67×10^{-3}) were 12
168 significant predominant pathways in PMR (Fig. 1C). The cytokine-mediated signaling
169 pathway, the positive regulation of IL-6 production, and the MyD88-dependent toll-
170 like receptor (TLR) signaling pathway were also significantly altered. KEGG analysis
171 revealed that the cytokine-cytokine receptor interaction was the most remarkable
172 pathway ($FDR\ 2.85 \times 10^{-5}$) (Fig. 1D). GO and KEGG results demonstrated patients
173 with PMR had significant inflammatory gene expression profiles.

174

175 **Abundant inflammatory genes that may activate Janus tyrosine kinase (JAK)** 176 **signaling**

177 Volcano results demonstrated that many genes expression were significantly
178 increased; for example, TLR8 ($p = 1.95 \times 10^{-20}$), IL17RA ($p = 3.27 \times 10^{-17}$), IL6R ($p =$
179 6.71×10^{-16}), CR1 ($p = 1.14 \times 10^{-14}$), TLR2 ($p = 2.99 \times 10^{-14}$), TLR4 ($p = 8.48 \times 10^{-14}$),
180 CCR1 ($p = 7.75 \times 10^{-13}$), JAK2 ($p = 6.57 \times 10^{-6}$), IL1R1 ($p = 1.72 \times 10^{-5}$), IL1B ($p = 2.87 \times$
181 10^{-5}), S100A8 ($p = 2.14 \times 10^{-3}$), and S100A12 ($p = 2.76 \times 10^{-3}$) (Fig. 2A).

182 We also confirmed that the above genes were all increased via Real-Time PCR (Fig.
183 2B). They can activate the JAK-signal transducer and activator of transcription (STAT)
184 pathway[8-18]. They were also related to the function of monocytes, T cells, and
185 neutrophils. The JAK-STAT pathway may be crucial in the pathogenesis of PMR.

186 **Tofacitinib therapy for patients with PMR**

187 As we know, glucocorticoids are the first-line drugs in the treatment of PMR.
188 However, they come with lots of side effects. Zhang et al. demonstrated that JAK1
189 and JAK3 were involved in chronic inflammation of media and large arteries in an
190 animal model of giant cell arteritis (GCA), JAK inhibitor (JAKi) tofacitinib effectively
191 suppressed innate and adaptive immunity in the vessel wall by reducing the
192 proliferation rates of lesional T cells and their interferon- γ , IL-17, and IL-21
193 expressions[19]. We demonstrated that the expression of JAK2 was increased in
194 PBMCs from patients with PMR (Figure 1B, C). Interestingly, Tofacitinib was tried in 3
195 patients with PMR as a steroid-sparing agent ([https://isr.ie/abstracts/a-review-of-
196 patients-started-on-janus-kinase-inhibitor-jaki-in-university-hospital-waterford/](https://isr.ie/abstracts/a-review-of-patients-started-on-janus-kinase-inhibitor-jaki-in-university-hospital-waterford/)).
197 Another JAKi Baricitinib lowered rapidly disease activity and exerted a significant
198 steroid-sparing effect in 6 cases with refractory PMR and/or GCA [20]. JAKi appears
199 as an appealing option for treating patients with PMR if they have refractory disease
200 course or other diseases such as diabetes mellitus or osteoporosis which is relatively
201 contraindicated for use of glucocorticoids. To some extent, RA and PMR are two
202 inflammatory diseases with similar manifestations. JAKi was used for the treatment
203 of RA. JAKi may be one choice for PMR. In our study, five patients with PMR refused
204 to take steroids for fear of their side effects, because four patients have osteoporosis.
205 They hopefully have a quick remission but no steroid or no injection such as
206 tocilizumab. They agree with oral Tofacitinib therapy. Dramatically, their pain
207 disappeared and many genes were decreased after tofacitinib therapy. One
208 representative case is shown in Fig. 2C, D. There were no adverse events such as
209 upper respiratory infection or herpes zoster during the 3–6-month period of
210 treatment with tofacitinib.

211 Furthermore, the gene expression profiles of patients with PMR that were in
212 remission after tofacitinib therapy (the PMR-C group) differed from those of patients
213 in the PMR-A group and were similar to those of HC group (Fig. 1B). These results

214 suggested that patients with PMR-C had attained complete serological remission
215 after tofacitinib therapy.

216 **Discussion**

217 PMR is a classic inflammatory disease with an acute onset but an unknown cause. IL-
218 6 is one of the key pro-inflammatory cytokines involved in the pathogenesis of PMR.
219 IL-6 and IL-1 β were increased in the inflamed trapezius and lateral femoral muscles
220 of PMR patients[8]. IL-6 can activate the JAK-STAT signaling via IL6R. Meanwhile, IL-
221 1 β binding to IL1R1 can form the high-affinity IL-1R complex, which mediates the
222 Nuclear factor kappa B (NF- κ B), Mitogen-activated protein kinase (MAPK), and JAK-
223 STAT activation and promotes the inflammatory response[9]. TLR2, TLR4, and TLR8
224 were highly expressed in peripheral blood leukocytes, particularly in monocytes and
225 macrophages. TLRs can lead to NF- κ B activation, cytokine secretion, and the
226 inflammatory response. TLR2/TLR4 in collaboration with the JAK-STAT signaling
227 regulates endotoxemia and inflammation[10, 11]. STAT-1 was required for TLR8
228 transcriptional activity[12]. Furthermore, TLR4 was associated with increased
229 susceptibility to PMR[21].

230 S100A8 and S100A12 are calcium-binding, zinc-binding proteins, and inflammatory
231 mediators. S100A8 can induce the JAK1/2-dependent signaling[13]. S100A12 was
232 induced by IL-6 via JAK signaling[14]. CCR1 and CR1 play critical roles in the process
233 of inflammation. CCR1 was involved in the regulation of smoke-induced
234 inflammation via JAK/STAT3 signaling[15]. CCR1 may also play a role in macrophage
235 and endothelial cell infiltration in experimental arthritis models partly through
236 activating JAK signaling[16]. Complement activation can be induced during
237 inflammation, which is further normalized by a JAK1/2 inhibitor[17]. The number of
238 Th17 cells was increased in the blood of PMR patients. CD161⁺CD4⁺T cells, which are
239 precursors of Th17 cells, differentiated into Th17 cells through STAT-1/STAT-3
240 phosphorylation[18]. We found that IL6R, IL1B, IL1R1, TLR2, TLR4, TLR8, S100A8,
241 S100A12, CCR1, CR1, and IL17RA expression was increased in PBMCs from patients
242 with PMR. These genes may be partly involved in the pathogenesis of PMR via JAK-
243 STAT signaling.

244 JAK1 and JAK3 were involved in chronic inflammation of media and large arteries
245 in an animal model of GCA, tofacitinib effectively suppressed innate and adaptive
246 immunity in the vessel wall [19]. Furthermore, five patients with PMR had a good
247 response to tofacitinib therapy in our study. We have registered a clinical trial titled
248 “a prospective study on the efficacy and safety of tofacitinib in the treatment of PMR”
249 (ChiCTR2000038253) on the website (<http://www.chictr.org.cn/>). More data will be
250 published in the future.

251 Our study has some limitations. The number of patients was small. We do not
252 finish the functional experiment of candidate genes involved in the pathogenesis of
253 PMR. PMR is closely associated with GCA. The patients with PMR in this study did not
254 simultaneously have a GCA. Further studies are needed to investigate the clinical
255 role and mechanism of action of candidate genes in PMR.

256

257 **Conclusion**

258 Many inflammatory genes associated with JAK signaling are highly enriched in
259 PBMCs from patients with PMR. Tofacitinib, a pan JAK inhibitor effectively treated
260 the PMR patients with clinical remission and sharply decreased in CRP and ESR in this
261 pre-clinical trial study. Tofacitinib may effectively treat PMR patients.

262

263 Disclosure statement: The authors have declared no conflicts of interest.

264

265 Funding: This work was supported in part by grants from Natural Science Foundation
266 of China (82171768).

267

268 Data availability statement: All the data can be available upon reasonable request.

269

270 **References**

- 271 1 Camellino D, Matteson EL, Buttgereit F, Dejaco C. Monitoring and long-term
272 management of giant cell arteritis and polymyalgia rheumatica. *Nat Rev Rheumatol*
273 2020;16(9):481-95.
- 274 2 Buttgereit F, Matteson EL, Dejaco C. Polymyalgia Rheumatica and Giant Cell
275 Arteritis. *Jama* 2020;324(10):993-4.

- 276 3 Prieto-Peña D, Castañeda S, Atienza-Mateo B, Blanco R, González-Gay MA.
277 Predicting the risk of relapse in polymyalgia rheumatica: novel insights. *Expert Rev*
278 *Clin Immunol* 2021;17(3):225-32.
- 279 4 Guggino G, Ferrante A, Macaluso F, Triolo G, Ciccia F. Pathogenesis of polymyalgia
280 rheumatica. *Reumatismo* 2018;70(1):10-7.
- 281 5 Carvajal Alegria G, Boukhhal S, Cornec D, Devauchelle-Pensec V. The
282 pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. *Autoimmun*
283 *Rev* 2020;19(11):102670.
- 284 6 Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-
285 year epidemiologic and clinical study. *Ann Intern Med* 1982;97(5):672-80.
- 286 7 Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. *Ann Rheum*
287 *Dis* 2004;63(10):1279-83.
- 288 8 Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of
289 inflammatory cytokines in polymyalgia rheumatica. *Arthritis Rheum*
290 2010;62(12):3768-75.
- 291 9 Biffi G, Oni TE, Spielman B, et al. IL1-Induced JAK/STAT Signaling Is Antagonized
292 by TGF β to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. *Cancer*
293 *Discov* 2019;9(2):282-301.
- 294 10 Paracha RZ, Ahmad J, Ali A, et al. Formal modelling of toll like receptor 4 and
295 JAK/STAT signalling pathways: insight into the roles of SOCS-1, interferon- β and
296 proinflammatory cytokines in sepsis. *PLoS One* 2014;9(9):e108466.
- 297 11 Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk among Jak-STAT, Toll-like receptor,
298 and ITAM-dependent pathways in macrophage activation. *J Leukoc Biol*
299 2007;82(2):237-43.
- 300 12 Zannetti C, Bonnay F, Takeshita F, et al. C/EBP δ and STAT-1 are required
301 for TLR8 transcriptional activity. *J Biol Chem* 2010;285(45):34773-80.
- 302 13 Diklić M, Mitrović-Ajtić O, Subotički T, et al. IL6 inhibition of inflammatory
303 S100A8/9 proteins is NF- κ B mediated in essential thrombocythemia. *Cell Biochem*
304 *Funct* 2020;38(4):362-72.
- 305 14 Hasegawa T, Kosaki A, Kimura T, et al. The regulation of EN-RAGE (S100A12)
306 gene expression in human THP-1 macrophages. *Atherosclerosis* 2003;171(2):211-8.
- 307 15 Zhao K, Dong R, Yu Y, et al. Cigarette smoke-induced lung inflammation in COPD
308 mediated via CCR1/JAK/STAT /NF- κ B pathway. *Aging (Albany NY)*
309 2020;12(10):9125-38.
- 310 16 Shahrara S, Amin MA, Woods JM, Haines GK, Koch AE. Chemokine receptor
311 expression and in vivo signaling pathways in the joints of rats with adjuvant-induced
312 arthritis. *Arthritis Rheum* 2003;48(12):3568-83.
- 313 17 Yan B, Freiwald T, Chauss D, et al. SARS-CoV-2 drives JAK1/2-dependent local
314 complement hyperactivation. *Sci Immunol* 2021;6(58).
- 315 18 Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing
316 CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis.
317 *Arthritis Rheum* 2012;64(11):3788-98.
- 318 19 Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of
319 JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large
320 Vessel Vasculitis. *Circulation* 2018;137(18):1934-48.
- 321 20 Camellino D, Dejaco C, Giusti A, et al. AB0379 Baricitinib in polymyalgia
322 rheumatica and giant cell arteritis: report of six cases. *Annals of the Rheumatic*
323 *Diseases* 2021;80(Suppl 1):1216-7.
- 324 21 Dejaco C, Duftner C, Buttgerit F, Matteson EL, Dasgupta B. The spectrum of
325 giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.
326 *Rheumatology (Oxford)* 2017;56(4):506-15.

327

328

329

330

331

332

333 **Table 1** Demographic and clinical parameters of PMR and healthy controls on study
334 entry

	PMR-A (n = 11)	Healthy controls (n =20)	P value
Age, mean \pm SD years	68.0 \pm 8.3	63.7 \pm 9.8	0.142
Female/male	10/1	17/3	0.67
Disease duration, mean \pm SD months	10.4 \pm 14.8	NA	
Pain, VS score 0-10, mean \pm SD	4.9 \pm 2.2	NA	
Physician global assessment, VS score 0-10, mean \pm SD	4.7 \pm 2.9	NA	
Morning stiffness, min, mean \pm SD	17.3 \pm 21.8	NA	
EUL, mean \pm SD	1.0 \pm 0.8	0	
CRP, mean \pm SD mg/dl	3.9 \pm 3.1	0.2 \pm 0.2	<0.0001
ESR, mean \pm SD mm/h	67.1 \pm 24.9	10.5 \pm 5.2	<0.0001
Disease activity scores, mean \pm SD	16.3 \pm 7.3	NA	

335 these PMR patients with high disease activity: PMR-A, NA: not applicable, VS: visual analogue scale,
336 EUL: ability to elevate the upper limbs; C-reactive protein (CRP), normal range 0–0.08 mg/dl;
337 Erythrocyte sedimentation rate (ESR), normal range 0–20mm/h.

338

339

340

341

342

343

344

345

346

347

348 **Figure legends**

349 **FIG. 1 The patients with PMR had a significant inflammatory gene expression**
350 **profile.**

351 **(A and B)** Principal component analysis (PCA) and heatmap showed that gene
352 expression of PBMCs was different among patients with active PMR (PMR-A, n=11),
353 with PMR in remission (PMR-C, n=5), and Healthy controls (HC, n=20) by RNAseq
354 analysis. **(C)** GO analysis demonstrated that inflammatory response (FDR 6.74×10^{-15} ,
355 58 significantly altered genes) and other 11 predominate pathways (PMR-A vs. HC).

356 **(D)** KEGG analysis showed cytokine-cytokine receptor interaction was the most
357 remarkable pathway (FDR 2.85×10^{-5} , 33 significantly altered genes) (PMR-A vs. HC).

358

359 **FIG. 2 An abundant inflammatory genes which may activate JAK signaling.**

360 **(A)** Volcano results demonstrated the many genes expression were significantly
361 increased, for example, TLR8, IL17RA, IL6R, CR1, TLR2, TLR4, CCR1 , JAK2, IL1R1, IL1B,
362 S100A8 , and S100A12 (PMR-A, n=11 vs. HC n=20). **(B)** They were all increased in

363 patients with PMR-A by Real-Time PCR analysis. Comparisons between two groups
364 were performed using the nonparametric Mann-Whitney test ($*p < 0.05$, $**p < 0.01$).

365 **(C)** Many genes were decreased in one representative patient with PMR. **(D)** She had
366 a significant decrease in PMR disease score, CRP, and ESR after the treatment with
367 tofacitinib.



